相关实验视频

Updated: Jan 11, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

口服PCSK9抑制剂作为脂质管理的新兴前沿:一个元分析

Vinh Q T Ho¹, Nghi Bao Tran¹, Nhan Nguyen¹

¹Faculty of Medicine, University of Debrecen, Debrecen, Hungary (Drs Ho, Tran, and Nguyen).

Journal of clinical lipidology

|November 13, 2025

概括

口服的プロ蛋白转化酶亚素/素9型抑制剂 (PCSK9i) 在高胆固醇血清症中有效降低了LDL-C,甘油三,阿波利波蛋白B和脂蛋白. 这些新的口服PCSK9i疗法显示出良好的安全性,为心血管风险管理提供了有前途的新选择.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
脂质代谢脂质代谢是什么

背景情况:

蛋白转化酶亚素/素9型抑制剂 (PCSK9i) 已被确立为高胆固醇血症的降脂剂.
最近开发的口服PCSK9i对注射配方具有潜在的优势.
这些药物对于控制动脉样硬化心血管疾病风险至关重要.

研究的目的:

评估口服PCSK9i在降低脂质水平方面的疗效,包括LDL-C,甘油三,阿波利波蛋白B和脂质蛋白.
与安慰剂相比,评估口服PCSK9i的安全性.
为了确定口服PCSK9i在高胆固醇血症标准医疗方案中的有效性.

主要方法:

随机对照试验的系统审查和元分析.
包括将口服PCSK9i与安慰剂进行比较的试验,这些试验是在接受稳定降脂疗法的高胆固醇患者中进行的.
在PubMed,Embase和Cochrane数据库中进行的搜索;对平均差异和赔率比率的综合分析.

主要成果:

对3项随机对照试验的分析,涉及1020名患者,其中804人接受口服PCSK9i.
观察到LDL-C (-47.83%),甘油三 (-11.65%),阿波利波蛋白B (-38.71%) 和脂蛋白 (a) (-19.80%) 的显著降低与口服PCSK9i.
没有注意到严重不良事件的显著增加 (OR = 0.74;P = .45).

结论:

口服PCSK9i可显著改善脂质特征,包括LDL-C,甘油三,阿波蛋白B和脂质蛋白 (a).
这些药物耐受性良好,不会增加严重不良事件的风险.
口服PCSK9i代表了一种有希望的,可访问的治疗选择,用于管理高胆固醇血清症和降低心血管风险.

关键词:

乙类阿波利波蛋白 (B) 是一种阿波利波蛋白.超高胆固醇血症是什么情况这就是为什么LDL胆固醇是LDL胆固醇.脂蛋白 (a) 是一种蛋白质口服使用的PCSK9抑制剂.三甲酸甘油三甲酸甘油是什么

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...